Home » Stocks » VLON

Vallon Pharmaceuticals, Inc. (VLON)

Stock Price: $4.98 USD 0.08 (1.63%)
Updated Jun 11, 2021 4:00 PM EDT - Market closed
After-hours: $5.10 +0.12 (2.41%) Jun 11, 5:33 PM
Market Cap 33.93M
Revenue (ttm) n/a
Net Income (ttm) n/a
Shares Out 5.71M
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day June 11
Last Price $4.98
Previous Close $4.90
Change ($) 0.08
Change (%) 1.63%
Day's Open 4.70
Day's Range 4.70 - 5.40
Day's Volume 294,974
52-Week Range 3.61 - 9.90

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

- Company remains on track to report p ivotal data from lead program , ADAIR, in second half 2021

1 month ago - GlobeNewsWire

- Financial executive bringing over 20 years of experience in accounting, finance and management with a foundation established from big four accounting firm

1 month ago - GlobeNewsWire

Live video webcast with David Baker, President and CEO of Vallon on Tuesday, May 18, 2021 at 4:15 PM ET

1 month ago - GlobeNewsWire

David Baker, President and CEO of Vallon to participate in the virtual Advances in Neuropsychiatry Panel on A pril 29 th at 10:30 AM ET

1 month ago - GlobeNewsWire

- Ongoing ADAIR SEAL study on target for pivotal data readout in second half of 2021 - Target NDA filing in Q2 2022 for a potential abuse-deterrent alternative to commercially available IR amphetamines ...

2 months ago - GlobeNewsWire

Pre-market movers on Tuesday include ZOM stock, RIOT stock and AGC stock, following all sorts of big stock market news. The post Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tue...

Other stocks mentioned: AGC, LYL, MFNC, NCBS, OBAS, RILY, RIOT ...
2 months ago - InvestorPlace

- Pivotal data from lead program, ADAIR, expected in second half 2021

2 months ago - GlobeNewsWire

PHILADELPHIA, PA, March 03, 2021 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals Inc. (NASDAQ: VLON), (“Vallon” or the “Company”), a clinical-stage biopharmaceutical company primarily focused on the developm...

3 months ago - GlobeNewsWire

- Accomplished executive leader with more than 30 years of experience in finance and operations

3 months ago - GlobeNewsWire

PHILADELPHIA, PA, Feb. 12, 2021 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals Inc. (NASDAQ: VLON) (“Vallon” or the “Company”), a clinical-stage biopharmaceutical company primarily focused on the developmen...

4 months ago - GlobeNewsWire

PHILADELPHIA, PA, Feb. 09, 2021 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals, Inc. (the “Company”), a clinical-stage biopharmaceutical company primarily focused on the development of novel drugs that are ...

4 months ago - GlobeNewsWire

Vallon Pharmaceuticals, a biopharma developing abuse-deterrent prescription drugs for CNS disorders, announced terms for its IPO on Thursday.

4 months ago - NASDAQ

Vallon Pharmaceuticals, Inc. has filed to go public with an IPO on the NASDAQ.

5 months ago - SEC

About VLON

Vallon Pharmaceuticals is a biopharmaceutical company primarily focused on the development and commercialization of proprietary biopharmaceutical products. We are developing prescription drugs for central nervous system (CNS) disorders and our current focus is the development of drugs with lower potential for abuse than currently available drugs. Our clinical-stage product currently under development is Abuse-Deterrent Amphetamine Immediate-Release, or ADAIR, a proprietary, abuse-deterrent oral formulation of immediate-release (short-acting) de... [Read more...]

Industry
Biotechnology
IPO Date
Feb 10, 2021
CEO
David Baker
Employees
2
Stock Exchange
NASDAQ
Ticker Symbol
VLON
Full Company Profile

Financial Performance

Financial Statements